GH - Guardant Health Inc Stock Price, Fair Value and News

17.05USD+0.98 (+6.10%)Delayed as of 22 Apr 2024, 12:25 pm ET

Market Summary

USD17.05+0.98

Delayedas of 22 Apr 2024, 12:25 pm

6.10%

GH Alerts

1 major insider buys recently.

GH Stock Price

View Fullscreen

GH RSI Chart

GH Valuation

Market Cap

2.0B

Price/Earnings (Trailing)

-4.08

Price/Sales (Trailing)

3.47

EV/EBITDA

-4.53

Price/Free Cashflow

-5.67

GH Price/Sales (Trailing)

GH Profitability

EBT Margin

-84.90%

Return on Equity

-302.14%

Return on Assets

-26.84%

Free Cashflow Yield

-17.64%

GH Fundamentals

GH Revenue

Revenue (TTM)

563.9M

Rev. Growth (Yr)

22.19%

Rev. Growth (Qtr)

8.41%

GH Earnings

Earnings (TTM)

-479.4M

Earnings Growth (Yr)

-33.67%

Earnings Growth (Qtr)

-117.23%

Breaking Down GH Revenue

52 Week Range

16.7941.06

(Low)(High)

Last 7 days

-11.9%

Last 30 days

-10.3%

Last 90 days

-30.7%

Trailing 12 Months

-34.6%

How does GH drawdown profile look like?

GH Financial Health

Current Ratio

6.54

Debt/Equity

7.18

Debt/Cashflow

-0.29

GH Investor Care

Shares Dilution (1Y)

18.55%

Diluted EPS (TTM)

-4.3

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	482.2M	510.2M	535.8M	563.9M
2022	391.1M	408.1M	430.8M	449.5M
2021	297.9M	323.7M	343.9M	373.7M
2020	245.2M	257.6M	271.3M	286.7M
2019	110.6M	145.2M	184.4M	214.4M
2018	60.0M	70.2M	80.4M	90.6M
2017	0	0	37.5M	49.8M
2016	0	0	0	25.2M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Guardant Health Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 15, 2024	tariq musa	acquired	-	-	249	-
Apr 15, 2024	saia john g.	sold (taxes)	-64,981	17.06	-3,809	chief legal officer
Apr 15, 2024	saia john g.	acquired	-	-	7,569	chief legal officer
Apr 15, 2024	potter myrtle s	acquired	-	-	68.00	-
Apr 04, 2024	joyce meghan v.	acquired	-	-	67.00	-
Apr 01, 2024	chudova darya	acquired	-	-	1,340	chief technology officer
Apr 01, 2024	kalia kumud	acquired	-	-	1,607	chief information officer
Apr 01, 2024	eagle craig	acquired	-	-	1,714	chief medical officer
Apr 01, 2024	freeman chris	acquired	-	-	1,929	chief commercial officer
Apr 01, 2024	chudova darya	sold (taxes)	-10,671	20.25	-527	chief technology officer

Which funds bought or sold GH recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 18, 2024	Allspring Global Investments Holdings, LLC	new	-	273,348	273,348	-%
Apr 18, 2024	SJS Investment Consulting Inc.	sold off	-100	-136	-	-%
Apr 18, 2024	ARK Investment Management LLC	reduced	-17.56	-4,399,760	7,450,850	0.05%
Apr 18, 2024	Citizens Business Bank	sold off	-100	-1,228,720	-	-%
Apr 18, 2024	MV CAPITAL MANAGEMENT, INC.	added	500	96.00	124	-%
Apr 17, 2024	BARRETT & COMPANY, INC.	sold off	-100	-13,525	-	-%
Apr 16, 2024	TSFG, LLC	unchanged	-	-1,000	2,000	-%
Apr 15, 2024	Wealthcare Advisory Partners LLC	sold off	-100	-232,522	-	-%
Apr 15, 2024	Sound Income Strategies, LLC	sold off	-100	-5,410	-	-%
Apr 15, 2024	Portman Square Capital LLP	sold off	-100	-256,272	-	-%

Are Funds Buying or Selling GH?

Are funds buying GH calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own GH

No. of Funds

GH Alerts

1 major insider buys recently.

Unveiling Guardant Health Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 12, 2024	deep track capital, lp	5.75%	7e+06	SC 13G
Feb 13, 2024	vanguard group inc	9.18%	11,130,601	SC 13G/A
Feb 09, 2024	fmr llc	-	0	SC 13G/A
Feb 09, 2024	capital international investors	3.4%	4,013,661	SC 13G/A
Jan 29, 2024	baillie gifford & co	5.24%	6,178,812	SC 13G
Jan 25, 2024	blackrock inc.	8.9%	10,831,716	SC 13G/A
Mar 10, 2023	fmr llc	-	0	SC 13G/A
Feb 14, 2023	viking global investors lp	4.0%	4,107,644	SC 13G/A
Feb 13, 2023	capital international investors	7.7%	7,879,355	SC 13G
Feb 13, 2023	capital research global investors	2.0%	2,001,782	SC 13G/A

Recent SEC filings of Guardant Health Inc

View All Filings

Date Filed	Form Type	Document
Apr 16, 2024	4	Insider Trading
Apr 16, 2024	4	Insider Trading
Apr 16, 2024	4	Insider Trading
Apr 12, 2024	SC 13G	Major Ownership Report
Apr 05, 2024	4	Insider Trading
Apr 02, 2024	4	Insider Trading
Apr 02, 2024	4	Insider Trading
Apr 02, 2024	4	Insider Trading
Apr 02, 2024	4	Insider Trading
Apr 02, 2024	4	Insider Trading

Peers (Alternatives to Guardant Health Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
DHR	174.2B	23.9B	-6.45%	-5.19%	36.72	7.29	-10.33%	-33.23%
IDXX	39.6B	3.7B	-10.02%	-2.89%	46.84	10.81	8.72%	24.44%
A	38.9B	6.7B	-9.88%	-2.07%	31.47	5.78	-2.81%	-6.58%
DGX	14.2B	9.3B	0.58%	-10.70%	16.65	1.54	-6.38%	-9.73%
CRL	11.6B	4.1B	-15.49%	14.49%	24.52	2.82	3.86%	-2.39%
MEDP	11.4B	1.9B	-6.78%	97.59%	40.46	6.07	29.17%	15.26%
EXAS	11.1B	2.5B	-2.68%	-8.07%	-54.22	4.43	19.93%	67.26%
NTRA	10.3B	1.1B	-8.21%	57.21%	-23.68	9.51	31.99%	20.63%
MID-CAP
NEOG	2.5B	929.2M	-25.64%	-30.20%	1.6K	2.71	28.93%	111.61%
GH	2.0B	563.9M	-10.26%	-34.59%	-4.08	3.47	25.45%	26.76%
SMALL-CAP
CDNA	430.3M	280.3M	-16.97%	-3.59%	-2.26	1.53	-12.89%	-148.37%
ACRS	87.9M	31.2M	5.04%	-86.38%	-0.99	2.81	5.03%	-1.81%
AWH	43.1M	9.2M	0.29%	-35.85%	-2.58	4.71	11.85%	44.12%
APDN	5.8M	9.0M	-32.00%	-67.31%	-0.8	0.64	-53.31%	2.21%
BIOC	183.8K	25.9M	-50.00%	-94.83%	-0.01	0.01	-57.78%	-93.11%

Guardant Health Inc News

Latest updates

Guardant Health Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	8.4%	155,054,000	143,030,000	137,150,000	128,714,000	126,891,000	117,404,000	109,144,000	96,099,000	108,108,000	94,779,000	92,101,000	78,665,000	78,316,000	74,569,000	66,335,000	67,510,000	62,897,000	60,848,000	53,975,000	36,655,000	32,873,000
Costs and Expenses	37.4%	352,565,000	256,573,000	256,766,000	262,769,000	273,010,000	262,004,000	239,465,000	219,437,000	206,316,000	202,067,000	189,743,000	186,528,000	169,482,000	148,821,000	120,955,000	102,422,000	88,859,000	78,325,000	69,243,000	60,319,000	60,260,000
S&GA Expenses	14.8%	79,127,000	68,934,000	71,043,000	76,123,000	81,423,000	80,370,000	73,603,000	64,432,000	59,599,000	50,228,000	47,716,000	34,338,000	31,288,000	25,095,000	25,015,000	25,115,000	22,287,000	18,802,000	19,439,000	17,807,000	17,114,000
R&D Expenses	-4.3%	89,856,000	93,851,000	90,359,000	93,128,000	106,578,000	100,017,000	85,455,000	81,757,000	73,021,000	70,968,000	63,724,000	55,508,000	40,282,000	36,245,000	36,319,000	37,016,000	25,875,000	24,569,000	19,532,000	16,316,000	16,652,000
EBITDA Margin	-6.7%	-0.77	-0.72	-0.91	-1.29	-1.37	-1.28	-1.23	-0.95	-0.96	-1.10	-1.06	-1.00	-	-	-	-	-	-	-	-	-
Interest Expenses	0.2%	645,000	644,000	645,000	644,000	644,000	644,000	645,000	644,000	643,000	644,000	644,000	646,000	4,736,000	8,000	10,000	12,000	321,000	280,000	287,000	293,000	299,000
Income Taxes	-210.4%	-541,000	490,000	496,000	240,000	602,000	115,000	446,000	-24,000	11,000	96,000	83,000	110,000	263,000	68,000	34,000	14,000	-489,000	-202,000	-1,207,000	26,000	35,000
Earnings Before Taxes	-119.1%	-187,584,000	-85,612,000	-72,275,000	-133,293,000	-139,332,000	-161,879,000	-228,986,000	-123,252,000	-72,300,000	-107,430,000	-97,492,000	-107,248,000	-92,782,000	-71,602,000	-49,705,000	-31,815,000	-22,599,000	-13,292,000	-12,507,000	-21,325,000	-25,237,000
EBT Margin	-5.7%	-0.85	-0.80	-0.99	-1.38	-1.45	-1.36	-1.30	-1.02	-1.03	-1.18	-1.14	-1.08	-	-	-	-	-	-	-	-	-
Net Income	-117.2%	-187,043,000	-86,102,000	-72,771,000	-133,533,000	-139,934,000	-161,994,000	-229,432,000	-123,228,000	-72,311,000	-107,526,000	-97,575,000	-107,358,000	-93,045,000	-71,670,000	-49,739,000	-31,829,000	-22,110,000	-13,090,000	-11,300,000	-21,351,000	-25,272,000
Net Income Margin	-5.4%	-0.85	-0.81	-1.00	-1.38	-1.46	-1.36	-1.30	-1.02	-1.03	-1.18	-1.14	-1.08	-	-	-	-	-	-	-	-	-
Free Cashflow	-3.3%	-82,805,000	-80,163,000	-100,528,000	-81,965,000	-100,750,000	-99,886,000	-134,969,000	-51,319,000	-101,613,000	-75,294,000	-81,268,000	-25,877,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-0.6%	1,786	1,797	1,840	1,512	1,610	1,702	1,854	2,130	2,204	2,226	2,292	2,347	2,272	1,262	1,278	948	963	948	940	579	587
Current Assets	0.0%	1,347	1,347	1,398	1,104	1,192	1,131	1,037	1,113	1,114	1,593	1,891	2,033	1,888	1,087	1,010	607	597	583	604	512	469
Cash Equivalents	147.9%	1,134	457	271	224	142	158	215	574	492	832	939	869	833	143	165	152	143	147	175	154	141
Inventory	-19.6%	62.00	77.00	61.00	46.00	52.00	63.00	60.00	37.00	31.00	25.00	26.00	29.00	23.00	28.00	20.00	25.00	15.00	15.00	14.00	10.00	9.00
Net PPE	-1.7%	145	148	156	163	168	168	163	151	124	106	90.00	72.00	63.00	62.00	57.00	47.00	44.00	41.00	35.00	31.00	31.00
Goodwill	0%	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	-	-	-
Liabilities	3.7%	1,628	1,569	1,547	1,556	1,550	1,535	1,535	1,597	1,559	1,457	1,444	1,440	916	114	113	118	115	86.00	78.00	65.00	62.00
Current Liabilities	-9.2%	206	227	201	204	193	175	168	229	195	102	97.00	96.00	67.00	72.00	70.00	82.00	73.00	68.00	57.00	48.00	47.00
Long Term Debt	0.1%	1,140	1,139	1,139	1,138	1,137	1,137	1,136	1,135	1,135	1,134	1,134	1,133	806	-	-	-	-	-	-	-	-
LT Debt, Non Current	0.1%	1,140	1,139	1,139	1,138	1,137	1,137	1,136	1,135	1,135	1,134	1,134	1,133	806	-	-	-	-	-	-	-	-
Shareholder's Equity	-30.5%	159	228	293	-	60.00	167	319	533	645	709	788	847	1,298	1,092	1,115	785	798	815	815	468	483
Retained Earnings	-9.6%	-2,141	-1,954	-1,868	-1,795	-1,662	-1,522	-1,360	-1,131	-1,007	-916	-809	-711	-606	-512	-435	-380	-352	-327	-314	-303	-280
Additional Paid-In Capital	5.3%	2,304	2,189	2,170	1,764	1,742	1,716	1,704	1,682	1,658	1,627	1,597	1,558	1,902	1,601	1,544	1,158	1,150	1,142	1,129	771	764
Shares Outstanding	3.2%	122	118	118	103	103	102	102	102	101	101	101	101	-	-	-	-	-	-	-	-	-
Float	-	-	-	4,100	-	-	-	4,000	-	-	-	12,100	-	-	-	7,600	-	-	-	3,400	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-1.2%	-78,728	-77,791	-94,015	-74,441	-90,749	-78,160	-111,935	-28,619	-76,988	-53,145	-62,593	-16,291	-59,223	-8,057	-23,365	-13,282	-30,342	1,347	-13,836	-4,303	-26,538
Share Based Compensation	11.5%	24,320	21,819	22,354	22,266	23,703	20,639	25,544	24,799	26,857	35,016	34,507	55,069	56,762	55,198	25,815	6,338	5,072	5,484	3,216	3,182	2,563
Cashflow From Investing	154.5%	663,454	260,699	-241,127	157,224	70,627	41,274	-72,893	110,808	-266,697	-47,394	127,066	123,870	-297,685	-14,656	-325,549	20,804	23,358	-35,730	-320,527	15,329	-197,688
Cashflow From Financing	2279.0%	90,568	3,807	383,854	-854	2,318	-19,312	-172,087	-12.00	3,780	-5,560	4,909	-69,953	1,046,724	797	361,320	1,466	3,077	6,871	355,068	2,288	250,364
Buy Backs	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

GH Income Statement

2023-12-31

Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Revenue:
Precision oncology testing	$ 514,249	$ 392,049	$ 304,312
Development services and other	49,699	57,489	69,341
Total revenue	563,948	449,538	373,653
Costs and operating expenses:
Cost of precision oncology testing	205,528	148,199	110,396
Cost of development services and other	21,524	8,126	12,516
Research and development expense	367,194	373,807	263,221
Sales and marketing expense	295,227	299,828	191,881
General and administrative expense	155,800	163,956	206,640
Other operating expense	83,400	0	0
Total costs and operating expenses	1,128,673	993,916	784,654
Loss from operations	(564,725)	(544,378)	(411,001)
Interest income	35,365	6,069	3,930
Interest expense	(2,578)	(2,577)	(2,577)
Other income (expense), net	53,174	(12,778)	25,178
Fair value adjustments of noncontrolling interest liability	0	(99,785)	0
Loss before provision for income taxes	(478,764)	(653,449)	(384,470)
Provision for income taxes	685	1,139	300
Net loss	(479,449)	(654,588)	(384,770)
Adjustment of redeemable noncontrolling interest	0	0	(20,900)
Net loss attributable to Guardant Health, Inc. common stockholders - basic	(479,449)	(654,588)	(405,670)
Net loss attributable to Guardant Health, Inc. common stockholders - diluted	$ (479,449)	$ (654,588)	$ (405,670)
Net loss per share attributable to Guardant Health, Inc. common stockholders, basic (in usd per share)	$ (4.28)	$ (6.41)	$ (4.00)
Net loss per share attributable to Guardant Health, Inc. common stockholders, diluted (in usd per share)	$ (4.28)	$ (6.41)	$ (4.00)
Weighted-average shares used in computing net loss per share attributable to Guardant Health, Inc. common stockholders, basic (in shares)	111,988	102,178	101,314
Weighted-average shares used in computing net loss per share attributable to Guardant Health, Inc. common stockholders, diluted (in shares)	111,988	102,178	101,314

GH Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 1,133,537	$ 141,647
Short-term marketable debt securities	35,097	869,584
Accounts receivable, net	88,783	97,256
Inventory, net	61,948	51,598
Prepaid expenses and other current assets, net	27,741	31,509
Total current assets	1,347,106	1,191,594
Property and equipment, net	145,096	167,920
Right-of-use assets, net	157,616	174,001
Intangible assets, net	8,979	11,727
Goodwill	3,290	3,290
Other assets, net	124,334	61,453
Total Assets	1,786,421	1,609,985
Current liabilities:
Accounts payable and accrued liabilities	187,952	175,817
Deferred revenue	17,965	17,403
Total current liabilities	205,917	193,220
Convertible senior notes, net	1,139,966	1,137,391
Long-term operating lease liabilities	185,848	210,015
Other long-term liabilities	96,006	9,179
Total Liabilities	1,627,737	1,549,805
Commitments and contingencies
Stockholders’ equity:
Preferred stock, par value of $0.00001 per share; 10,000,000 shares authorized, no shares issued and outstanding as of December 31, 2023 and 2022	0	0
Common stock, par value of $0.00001 per share; 350,000,000 shares authorized as of December 31, 2023 and 2022; 121,629,861 and 102,619,383 shares issued and outstanding as of December 31, 2023 and 2022, respectively	1	1
Additional paid-in capital	2,304,220	1,742,114
Accumulated other comprehensive loss	(3,675)	(19,522)
Accumulated deficit	(2,141,862)	(1,662,413)
Total Stockholders’ Equity	158,684	60,180
Total Liabilities and Stockholders’ Equity	$ 1,786,421	$ 1,609,985

About Guardant Health Inc

Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360; Guardant360 LDT; Guardant360 CDx; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It also offers Shield Test; Guardant Reveal Test for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, a suite of advanced analytical technologies to enhance the performance and clinical utility of cancer tests. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, and kits fulfillment related services to biopharmaceutical companies and medical institutions. Guardant Health, Inc. has a research collaboration agreement with the Parker Institute for Cancer Immunotherapy to study the correlation between molecular cancer biomarkers and patient response to immunotherapy treatment across various types of cancer. The company was incorporated in 2011 and is headquartered in Palo Alto, California.

CEO	Dr. Helmy Eltoukhy Ph.D.
WEBSITE	https://guardanthealth.com
INDUSTRY	Diagnostics & Research
EMPLOYEES	1793

Guardant Health Inc Frequently Asked Questions

What is the ticker symbol for Guardant Health Inc? What does GH stand for in stocks?

GH is the stock ticker symbol of Guardant Health Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Guardant Health Inc (GH)?

As of Fri Apr 19 2024, market cap of Guardant Health Inc is 1.96 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of GH stock?

You can check GH's fair value in chart for subscribers.

What is the fair value of GH stock?

You can check GH's fair value in chart for subscribers. The fair value of Guardant Health Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Guardant Health Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for GH so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Guardant Health Inc a good stock to buy?

The fair value guage provides a quick view whether GH is over valued or under valued. Whether Guardant Health Inc is cheap or expensive depends on the assumptions which impact Guardant Health Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for GH.

What is Guardant Health Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Apr 19 2024, GH's PE ratio (Price to Earnings) is -4.08 and Price to Sales (PS) ratio is 3.47. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. GH PE ratio will change depending on the future growth rate expectations of investors.